相关实验视频

Updated: Jun 29, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

在高级黑色素瘤中利用ctDNA:为明智的临床决策提供有前途的工具

Rugile Pikturniene^1,2, Alvydas Cesas², Sonata Jarmalaite^1,3

¹Life Sciences Center, Institute of Biosciences, Vilnius University, 7 Sauletekio Ave, 01513 Vilnius, Lithuania.

|March 28, 2024

概括

循环瘤DNA (ctDNA) 显示为高级黑色素瘤的基于血液的生物标志物,有助于预后和监测免疫疗法和向疗法的治疗反应.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
生物标志物生物标志物

背景情况:

皮肤黑色素瘤是一种具有不断发展的治疗策略的侵袭性癌症.
目前的监测方法,如成像扫描,有局限性.
在黑色素瘤管理中需要精确,动态的生物标志物.

研究的目的:

审查循环瘤DNA (ctDNA) 在晚期黑色素瘤中的作用.
涵盖技术方面,检测方法以及ctDNA的预后/预测价值.
突出ctDNA在临床实践中的潜力,以提供个性化护理.

主要方法:

关于晚期黑色素瘤中ctDNA的综合文献综述.
分析ctDNA的技术方面和检测方法.
评估ctDNA与黑色素瘤突变和治疗反应的关联.

主要成果:

ctDNA显示出作为一种基于血液的生物标记物的巨大潜力.
ctDNA有助于预测预后和监测治疗反应.
ctDNA可以帮助识别对疗法的耐药性机制.

结论:

ctDNA代表了高级黑色素瘤临床决策的范式转变.
它为个性化和知情的患者护理提供了一个有希望的轨迹.
ctDNA促进了动态监测,并指导免疫治疗和向治疗的治疗决策.

关键词:

生物标志物生物标志物 ctDNActDNA是什么意思免疫疗法免疫疗法黑色素瘤是一种黑色素瘤.

更多相关视频

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...